

Amendments to the Claims:

Claims 27, 44, 48 and 63 are currently amended. Claims 53 - 56, 66 and 67 are cancelled.

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1. - 26. (canceled).

27. (currently amended). An isolated C140 receptor polypeptide having at least 15 consecutive amino acids encoded by a nucleic acid molecule which hybridizes under stringent conditions to a nucleic acid molecule selected from the group consisting of : (a) a nucleic acid molecule complimentary to SEQ ID NO:3, and (b) a nucleic acid molecule complimentary to SEQ ID NO:62, wherein the stringent conditions are: (1) hybridization in 50% (vol/vol) formamide with 0.1% bovine serum albumin, 0.1% Ficoll, 0.1% polyvinylpyrrolidone, 50 mM sodium phosphate buffer at pH 6.5 with 750 mM NaCl and 75 mM sodium citrate at 42°C; or (2) hybridization in 50% formamide, 5 X SSC (750 mM NaCl, 75mM sodium citrate), 50 mM sodium phosphate (pH 6.8), 0.1% sodium pyrophosphate, 5 X Denhardt's solution, sonicated salmon sperm DNA (50 mu g/ml), 0.1% SDS, and 10% dextran sulfate 42°C, with washes at 42°C in 0.2 X SSC and 0.1% SDS or with washes at 50°C in 15 mM NaCl, 1.5 mM sodium citrate, and 0.1% sodium dodecyl sulfate.

28. (previously presented). The isolated polypeptide of claim 27, wherein the polypeptide comprises at least about 75% amino acid sequence identity with either of SEQ ID NOS: 4, or 63.

29. - 43. (canceled)

44. (currently amended). An isolated C140 receptor polypeptide comprising an amino acid sequence at least 95% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:4 and SEQ ID NO: 63.

45. (previously presented). The isolated polypeptide of claim 44, wherein the polypeptide comprises an amino acid sequence at least 95% identical to SEQ ID NO: 4.
46. (previously presented). An isolated fragment of a polypeptide selected from the group consisting of SEQ ID NO:4 and SEQ ID NO:63, wherein the fragment is at least 10 consecutive amino acids in length.
47. (previously presented). The isolated fragment of claim 46 consisting of a fragment of SEQ ID NO:63.
48. (currently amended). The isolated polypeptide of claim 44 which comprises the amino acid ~~sequences~~ sequence of SEQ ID NO:63.
49. (previously presented). The isolated polypeptide of claim 45 which comprises the amino acid sequence of SEQ ID NO:4.
50. (previously presented). The isolated polypeptide of claim 27, wherein the polypeptide comprises at least about 90% amino acid sequence identity with SEQ ID NO: 4.
51. (previously presented). The isolated polypeptide of claim 27, wherein the polypeptide comprises at least about 90% amino acid sequence identity with SEQ ID NO: 63.
52. (previously presented). The isolated polypeptide of claim 27, wherein the polypeptide comprises an activated C140 receptor.
53. - 56. (cancelled)
57. (previously presented). The isolated fragment of claim 46, comprising at least 20 amino acids in length.

58. (previously presented). The isolated fragment of claim 46, comprising at least 40 amino acids in length.
59. (previously presented). The polypeptide of claim 27 wherein the polypeptide has a biological activity in common with C140.
60. (previously presented). The polypeptide of claim 59 wherein the biological activity is a C140 receptor function.
61. (previously presented). The polypeptide of claim 59 wherein the biological activity is a C140 effector function.
62. (previously presented). The polypeptide of claim 59 wherein the biological activity is cross-reactive antigenicity with C140.
63. (currently amended). An isolated C140 receptor polypeptide comprising the fragment according to claim 46.
64. (previously presented). The polypeptide of claim 63 wherein the fragment is a fragment of SEQ ID NO:63.
65. (previously presented). The polypeptide of claim 63 wherein the fragment is a fragment of SEQ ID NO:4.
66. - 67. (cancelled)
68. (previously presented). The polypeptide of claim 63, wherein the polypeptide is at least 20 amino acids in length.

69. (previously presented). The polypeptide of claim 63, wherein the polypeptide is at least 40 amino acids in length.